dRx Capital
dRx Capital invests in exceptional entrepreneurs transforming healthcare through data and digital technology, focusing on AI/ML, big data, R&D optimization, patient care, and pharma supply chain and commercialization.
About dRx Capital
dRx Capital appears in the source data as a healthcare-focused investment entity with LinkedIn and Crunchbase footprint but no disclosed website, thesis, stage focus, or check size. The name strongly signals a digital prescription, prescription drug, or pharmaceutical-adjacent thesis, possibly a corporate venture vehicle from a pharmaceutical or pharmacy benefits company, given naming conventions in this category. dRx Capital was historically associated with a Novartis and Qualcomm joint venture focused on connected health and digital therapeutics, though the current operating status would need verification. For healthcare AI founders, the relevant fit, if the entity is currently active, would be for AI applications in digital therapeutics, medication adherence, prescription drug optimization, pharmaceutical commercial AI, or adjacent pharmacy-and-pharma ecosystem plays. Founders building broadly horizontal healthcare AI without a clear pharmaceutical or prescription angle are unlikely to find a fit. Plausible check sizing for corporate venture-style healthcare investors at this profile is $1M to $5M at Series A, with strategic value through the parent company’s commercial relationships often outweighing the financial check itself. The lack of disclosed website makes diligence harder; founders should pre-qualify the entity’s current operating status and parent affiliation through Crunchbase and LinkedIn before significant pitch preparation. Entry path is LinkedIn outreach to the leadership with a short, specific note that frames your AI thesis in pharmaceutical or prescription terms, asking directly about the entity’s current investment activity and check capacity. Treat as a niche opportunity that requires verification before meaningful founder time investment.
Founder reviews
Other portfolio companies
Companies in dRx Capital's portfolio not currently in our directory.
- Yseop · 2023
- Octave Bioscience · 2023
- RxLightning · 2023
- Peptone · 2022
- Science 37
- Aktana
- Animantis
- Aspen RxHealth
- Cala Health
- Cota Health
- Flywheel
- Freenome
Team
Pitch / review this investor
Have you raised from dRx Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).